Last reviewed · How we verify
Lumigan (BIMATOPROST)
Lumigan works by increasing the outflow of fluid from the eye to reduce pressure.
Lumigan (Bimatoprost) is a prostaglandin analog developed by originally developed by GlaxoSmithKline, now owned by Abbvie. It targets the Aldo-keto reductase family 1 member C3 enzyme and is used to treat hypertrichosis of eyelid, ocular hypertension, and open-angle glaucoma. Lumigan is a small molecule drug that has been FDA-approved since 2001 and is available as a generic medication from multiple manufacturers. As a prostaglandin analog, it works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. Despite its commercial availability, key safety considerations include potential eye irritation and changes in eye color.
At a glance
| Generic name | BIMATOPROST |
|---|---|
| Sponsor | Abbvie |
| Drug class | Prostaglandin Analog [EPC] |
| Target | Aldo-keto reductase family 1 member C3 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2001 |
Mechanism of action
Bimatoprost, prostaglandin analog, is synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Approved indications
- Hypertrichosis of eyelid
- Ocular hypertension
- Open-angle glaucoma
Common side effects
- conjunctival hyperemia
- ocular pruritus
- growth of eyelashes
- ocular dryness
- visual disturbance
- ocular burning
- foreign body sensation
- eye pain
- pigmentation of the periocular skin
- blepharitis
- cataract
- superficial punctate keratitis
Key clinical trials
- AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension (PHASE1,PHASE2)
- Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use (PHASE4)
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) (PHASE3)
- Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) (PHASE3)
- Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy
- Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (PHASE2,PHASE3)
- Evaluation of the Safety and Effectiveness of the Bimatoprost Implant System / IOL Combination in Patients With Ocular Hypertension or Mild to Moderate Open-angle Glaucoma (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 10314780 | 2036-06-08 | Formulation |
| 8206737 | 2027-04-07 | Method of Use |
| 9980974 | 2034-10-31 | Method of Use |
| 9492316 | 2034-10-31 | Formulation |
| 7799336 | 2029-04-24 | Formulation |
| 8629185 | 2031-07-15 | Compound |
| 10441543 | 2026-12-19 | Formulation |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lumigan CI brief — competitive landscape report
- Lumigan updates RSS · CI watch RSS